{'fraction_non_alphanumeric': 0.008849557522123894, 'fraction_numerical': 0.0, 'mean_word_length': 5.658823529411765, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Neurotoxicity in a phase I trial of continuous‐infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer

Both twice daily fractionated radiotherapy and concurrent cisplatin with once‐daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. The objective of this phase I trial was to determine the maximum tolerated dose of cisplatin which could be given as a continuous infusion concurrent with twice‐daily radiotherapy to patients with locally advanced head and neck cancer.